Comparison of the effect of oral and transdermal hormone therapy on fasting and postmethionine homocysteine levels

Fertility and Sterility

Volumn 81, Issue 1, 2004, Pages 99-103

  Cagnacci, Angelo ^a   Malmusi, Stefania ^a   Zanni, Anna Lisa ^a   Alessandrini, Chiara ^a   Caretto, Simona ^a   Volpe, Annibale ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cardiovascular risk; E2; Homocysteine; Hormonal replacement therapy; Menopause; Norethisterone

Indexed keywords

COMBESTRIL; CYANOCOBALAMIN; CYSTEINE; ESTRADIOL PLUS NORETHISTERONE ACETATE; FOLIC ACID; HOMOCYSTEINE; HORMONE; METHIONINE; NORETHISTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HEALTH SERVICE; HORMONAL THERAPY; HUMAN; OUTPATIENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; UNIVERSITY HOSPITAL;

EID: 0346095180     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.05.026     Document Type: Article

References (33)

1. Finkelstein J.D., Martin J.J., Harris B.J. Methionine metabolism in mammals the methionine-sparing effect of cystine . J Biol Chem. 263:1988;11750-11754.
2. Ueland P.M., Refsum H., Stabler S.P., Malinow M.R., Andersson A., Allen R.H. Total homocysteine in plasma or serum methods and clinical applications . Clin Chem. 39:1993;1764-1779.
3. Lowering blood homocysteine with folic acid based supplements meta-analysis of randomized trials . BMJ. 316:1998;894-898.
4. Mudd S.H., Havlik R., Levy H.L., McKusick V.A., Feinleib M. A study of cardiovascular risk in heterozygotes for homocystinuria. Am J Hum Genet. 33:1981;883-893.
5. Kozich V., Kraus E., de Franchis R., Fowler B., Boers G.H., Graham I., et al. Hyperhomocysteinemia in premature arterial disease examination of cystathionine beta-synthase alleles at the molecular level . Hum Mol Genet. 4:1995;623-629.
6. Malinow M.R. Plasma homocysteine and arterial occlusive diseases a mini review . Clin Chem. 41:1995;173-176.
7. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057.
8. Mangoni A.A., Jackson S.H.D. Homocysteine and cardiovascular disease current evidence and future prospects . Am J Med. 112:2002;556-565.
9. Cattaneo M., Martinelli I., Mannucci P.M. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 335:1996;974-976.
10. Peterson J.C., Spence J.D. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet. 351:1998;263.
11. Schnyder G., Roffi M., Pin R., Flammer Y., Lange H., Eberli F.R., et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 345:2001;1593-1600.
12. Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattström L.E., Ueland P.M., et al. Plasma homocysteine as a risk factor for vascular disease. JAMA. 277:1997;1775-1781.
13. Wilcken D.E.L., Gupta V.J. Cysteine-homocysteine mixed disulphide differing plasma concentrations in normal men and women . Clin Sci. 57:1979;211-215.
14. Nygard O., Vollset S.E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J.E., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 274:1995;1526-1533.
15. Morris M.S., Jacques P.F., Selhub J., Rosenberg I.H. Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 152:2000;140-148.
16. Andersson A., Hultberg B., Brattstrom L., Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Biochem. 30:1992;377-379.
17. Boers G.H.J., Smals A.G.H., Trijbels J.M.F., Leermakers A.I., Kloppenborg P.W. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest. 72:1983;1971-1976.
18. Brattström L.E., Hultberg B.L., Hardebo J.E. Folic acid responsive postmenopausal homocysteinemia. Metabolism. 34:1985;1073-1077.
19. Hak A.E., Polderman K.H., Westendorp I.C.D., Jakobs C., Hofman A., Witteman J.C.M., et al. Increased plasma homocysteine after menopause. Atherosclerosis. 149:2000;163-168.
20. Giltay E.J., Hoogeveen E.K., Elbers J.M., Gooren L.J., Asscheman H., Stehouwer C.D. Effects of sex steroids on plasma total homocysteine levels a study in transsexual males and females . J Clin Endocrinol Metab. 83:1998;550-553.
21. Giri S., Thompson P.D., Taxel P., Contois J.H., Otvos J., Allen R., et al. Oral oestrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis. 137:1998;359-366.
22. Mijatovic V., Kenemans P., Netelembos C., Jakobs C., Popp-Snijders C., Peters-Muller E.R., et al. Postmenopausal oral 17-β-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril. 69:1998;876-882.
23. Van der Mooren M.J., Wouters M.G., Bolm H.J., Eskes T.K., Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest. 24:1994;733-736.
24. Van Baal W.M., Smolders R.G., van der Mooren M.J., Teerlink T., Kenemans P. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol. 94:1999;485-491.
25. Barnabei V.M., Philips T.M., Hsia J. Plasma homocysteine in women taking hormone replacement therapy the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial . J Womens Health Gend Based Med. 8:1999;1167-1172.
26. Walsh B.W., Paul S., Wild R.A., Tracy R.P., Cox D.A., Anderson P.W. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women a randomised controlled trial . J Clin Endocrinol Metab. 85:2000;214-218.
27. Ventura P., Cagnacci A., Malmusi S., Panini R., Baldassari F., Arangino S., et al. Continuous combined hormone replacement therapy with oral 17β-estradiol and norethisterone acetate improves homocysteine metabolism in postmenopausal women. Menopause. 8:2001;252-258.
28. Eviö S., Tiitinen A., Turpeinen U., Ylikorkala O. Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil Steril. 74:2000;1081-1083.
29. Berger P.B., Herrmann R.R., Dumesic D.A. The effect of estrogen replacement therapy on total plasma homocysteine in healthy postmenopausal women. Mayo Clin Proc. 75:2000;18-23.
30. Smolders R.G.V., van der Mooren M.J., Teerlink T., Merkus J.M.W.M., Kroeks M.V.A.M., Franke H.R., et al. A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels. Fertil Steril. 79:2003;261-267.
31. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks and benefits. Menopause 2002;9:6-15.
32. Somekawa Y, Kobayashi K, Tomura S, Aso T, Hamaguchi H. Effects of hormone replacement therapy and methylenetetrahydrofolate reductase polymorphism on plasma folate and homocysteine levels in postmenopausal Japanese women. Fertil Steril 2002;77:481-6.
33. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol. 184:2001;255-263.